北京若生智能科技有限公司
Drug Database
PR

prednisolone

✓ Approved

Takeda · NR3C1 · 小分子

什么是 prednisolone？

prednisolone 是一种小分子，由Takeda研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

公司Takeda
药物类别小分子
分子靶点NR3C1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Takeda

作用机制

分子靶点

prednisolone 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prednisolone 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

相关研究文献

PubMedInternal medicine (Tokyo, Japan)2026-09-09

A Diagnostic Approach to Giant Cell Arteritis Initially Presenting with Infarction without Headache Using MR Vessel Wall Imaging and a Temporal Artery Biopsy: A Case Report.

Yamamoto Masaomi M, Dembo Tomohisa T, Sawada Keisuke K, Yoshida Yuichi Y et al.

A 75-year-old woman presented with a sudden onset of left homonymous hemianopia and dizziness without headache. Magnetic resonance imaging revealed multiple posterior circulation infarctions, and magnetic resonance angiography revealed right vertebral artery occlusion and left vertebral artery stenosis. Vessel wall imaging (VWI) revealed concentric wall thickening with enhancement, suggesting vasculitis. 18F-FDG PET/CT revealed an increased aortic uptake. Despite elevated CRP and ESR levels, the temporal artery ultrasound was normal. A biopsy confirmed giant cell arteritis (GCA). Prednisolone and tocilizumab normalized the inflammatory markers. This case shows that GCA can present without classic symptoms, and VWI may help evaluate unexplained vascular lesions without conventional risk factors.

PMID 42716740
阅读全文 →
PubMedInternal medicine (Tokyo, Japan)2026-09-09

Immunotactoid Glomerulopathy Diagnosed by a Repeat Kidney Biopsy After Initially Non-diagnostic Electron Microscopic Findings: A Case Report.

Yamada Muneharu M, Nagashima Masataka M, Aoki Ken K, Hoshino Takahiko T et al.

Immunotactoid glomerulopathy (ITG) is diagnosed by identifying organized microtubules on electron microscopy and it can therefore be missed when they are not demonstrated. A 48-year-old woman with hematuria, nephrotic-range proteinuria, and a faint IgG-κ monoclonal protein underwent an initial kidney biopsy, which showed endocapillary proliferative glomerulonephritis with membranoproliferative features and scant subendothelial deposits, but no diagnostic microtubules. With worsening renal dysfunction and a limited corticosteroid response, a repeat biopsy revealed IgG3-κ-restricted deposits and non-branching, hollow-core microtubules, confirming ITG associated with monoclonal gammopathy of renal significance. Rituximab-based B cell-directed therapy was followed by sustained remission with prednisolone tapered to 2.5 mg every other day.

PMID 42716754
阅读全文 →
PubMedAustralian veterinary journal2026-09-09

Ocular and cutaneous infection due to Curvularia pseudobrachyspora in an immunosuppressed dog: Case report and in vitro antimycotic susceptibilities.

Brasil-Ervedosa T T, Clark R R, Granados-Soler J J, Palmieri C C et al.

A 3-year-old male Border Collie diagnosed with immune-mediated dermatopathy, managed with tapering prednisolone and cyclosporine, developed rapidly progressive ocular signs and additional cutaneous lesions. Histopathology, mycological culture, polymerase chain reaction and sequencing confirmed intraocular and cutaneous infection due to Curvularia pseudobrachyspora and nasal squamous cell carcinoma. Upon confirmation of cutaneous infection, systemic antifungal therapy was initiated, but the clinical signs worsened and the patient died. Given the lack of guidelines for treatment of C. pseudobrachyspora, this patient's isolates were tested, and the minimum concentration and minimum effective concentration were obtained for selected antifungal drugs commonly used in veterinary medicine and compared to common filamentous and yeast fungal infections in dogs to provide general guidance into the treatment of this fungal species. Commonly utilised antifungal treatments used for common Aspergillus infections may prove ineffective against other filamentous fungi. Therefore, in the absence of standardised guidelines, each isolate should be assessed for appropriate treatment options.

PMID 42714271
阅读全文 →
PubMedIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2026-09-09

Clinical Profile and Treatment Outcomes of Adult Non-Pulmonary Langerhans Cell Histiocytosis from a Tertiary Care Hospital in South India.

Rudresha A H AH, Maleyur Vivek B VB, Asutkar Kartik G KG, SureshBabu M C MC et al.

Langerhans Cell Histiocytosis (LCH) is a haematological malignancy characterized by the clonal Langerhans cells proliferation. There is paucity of data on adult patients with LCH in India. We reviewed 18 patients of Adult Non-Pulmonary LCH treated at our institute from 2019 to 2024. Their Clinico-pathological features, treatment given and survival were studied. Median age at diagnosis was 30 years. 61% were males. 61% patients presented with bone lesions and 50% with lymphadenopathy. Immuno-Histochemistry (IHC) for CD1a, S100 were positive in all cases. 20% of the tested patients were positive for BRAF V600E mutation. 61% cases were multisystem LCH. Diabetes insipidus was seen in 4 patients (22%). 2 patients underwent curettage of the bone, 1 received radical Radiation therapy. 15 received systemic treatment: 9 received Vinblastine-prednisolone (LCH-3 Protocol) and 6 received cytarabine. Overall response rate was 78%. Median progression free survival was 34 months and median overall survival not reached after a median follow up of 42 months. This study adds to the few case reports of Adult LCH among Indian patients and helps in better understanding of their presentation and responses to therapy. Cytarabine and LCH 3 protocol show good long-term survival in Indian patients. The online version contains supplementary material available at https://doi.org/10.1007/s12288-025-02278-3.

PMID 42712716
阅读全文 →
PubMedCurrent pharmaceutical design2026-09-08

Preparation and Characterization of Prednisolone-Loaded Solid Lipid Nanoparticles for Potential Transdermal Application.

Hasnol Sabrina Mohamed SM, Affandi Meor Mohd Redzuan Meor Mohd MMRMM, Tin Wui Wong W, Anuar Nor Khaizan NK

Transdermal delivery of prednisolone using solid-lipid nanoparticles (SLN) offers a promising strategy to enhance drug administration by enabling direct transport through the skin into the systemic circulation. However, the impact of processing conditions on the physicochemical properties and release mechanisms of prednisolone‑loaded SLN remains insufficiently explored. The present study developed prednisolone-loaded SLN using an emulsification-homogenization- ultrasonication approach. Key process parameters, namely homogenization stirring speed and duration, as well as ultrasonication time, temperature, and power, were systematically refined based on particle size, polydispersity index (PDI), and zeta potential. The selected formulation was further characterized for entrapment efficiency (EE), drug loading (DL), attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and in vitro drug release. The experimentally determined DL ranged from 8.52 ± 0.55 to 9.89 ± 1.73%, corresponding to 85-99% of the intended loading, indicating minimal processing loss. Formulation H3, selected for further characterization based on its physicochemical profile, was homogenized at 10,000 rpm for 4 minutes, followed by ultrasonication at 60°C and 60 W for 4 minutes. H3 exhibited a particle size of 319.00 ± 56.15 nm, a PDI of 0.48 ± 0.022, a zeta potential of -19.86 ± 9.56 mV, and an EE of 98.25 ± 0.49%. All formulations demonstrated sustained drug release over 24 h with no statistically significant differences observed among them (p = 0.148). Kinetic modeling showed that both Higuchi and Korsmeyer-Peppas models adequately described the release profile of H3, suggesting heterogeneous release behavior involving overlapping diffusion- and matrix- related mechanisms. ATR-FTIR and DSC analyses indicated alterations in intermolecular interactions and lipid packing behavior following nanoparticle formation, while TEM confirmed spherical morphology and absence of visible aggregation, consistent with successful formation of the SLN system. Prednisolone-loaded SLN prepared using emulsification-homogenization-ultrasonication demonstrated favorable physicochemical properties and sustained release behavior governed by combined diffusion and matrix-related processes. Further studies on long-term stability, as well as ex vivo and in vivo skin permeation, are required to confirm their suitability for transdermal application.

PMID 42708316
阅读全文 →
PubMedAnalytical methods : advancing methods and applications2026-09-08

Development of a rapid colorimetric method for detection of synthetic corticosteroids in food and dietary supplements.

Pandey Shubhangi S, Pradhan Nishita N, Rai Pawankumar P, Sharma Sandeep K SK

Synthetic corticosteroids such as dexamethasone and prednisolone are widely used for the treatment of various conditions including tumors and skin disorders. Chronic exposure to synthetic corticosteroids leads to adverse health effects such as osteoporosis, hyperglycemia and hypertension. Several dietary and health supplements have recently been reported to be adulterated with synthetic corticosteroids. Conventional analytical techniques such as high-performance liquid chromatography (HPLC), thin-layer chromatography (TLC) and immunochromatography used for detection of these corticosteroids are time-consuming and require trained personnel, necessitating the development of rapid and cost-effective screening methods to ensure food safety. Here, a rapid and cost-effective colorimetric recognition chemistry has been developed for detection of synthetic corticosteroids in dietary supplements. The method employs spectrophotometric quantification of the chromogenic end product at 410 nm, which was further assessed using RGB-based image analysis. Selectivity and interference studies showed no significant matrix interference from the tested structurally similar steroids and common dietary supplement samples. The assay demonstrated a limit of detection (LOD) of 0.04 ± 0.008% (w/v) and a limit of quantification (LOQ) of 0.12 ± 0.027% (w/v) for prednisolone. The developed method is suitable for on-site detection of synthetic corticosteroids, and can be used by regulatory agencies and industries to ensure food safety and human health.

PMID 42709044
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多prednisolone